BIOMAT Database Logo BIOMAT Database Logo

A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. 1994

H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Department of Medicine, University Hospital of Zurich, Switzerland.

A phase I/IIA clinical trial with the chimeric mouse-human monoclonal antibody CGP 47,439 to the principal neutralization determinant in the V3 region of human immunodeficiency virus type 1 (HIV-1) strain IIIB envelope protein gp120 is reported. The trial was an uncontrolled single-center, open-label, multidose tolerability, immunogenicity, and pharmacokinetic study in homosexual men with advanced HIV disease. Patient groups were formed on the basis of the reactivity of the antibody with the gp120 of their HIV-1 isolates. Intravenous infusions of 1, 10, and 25 mg of antibody were followed by seven escalated doses of 50, 100, and 200 mg, every 3 weeks. The antibody was well tolerated; no toxicity was observed. Some patients showed a transient but insignificant antibody response to the antibody with no apparent adverse reactions or accelerated elimination of it. Substantial serum levels of the antibody were maintained with a mean t1/2 beta of 8-16 days. A virus burden reduction was observed in some patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.
October 2003, Virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop.
June 1994, Virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120.
December 1991, Proceedings of the National Academy of Sciences of the United States of America,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
March 1994, Virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Molecular mimicry between the human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins.
December 1993, Journal of virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120.
January 1993, Antisense research and development,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
July 1993, The Journal of general virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
February 1994, Journal of virology,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1).
April 1999, Immunology letters,
H F Günthard, and P L Gowland, and J Schüpbach, and M S Fung, and J Böni, and R S Liou, and N T Chang, and P Grob, and P Graepel, and D G Braun
Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
November 1990, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!